EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399

Ryan D Gentzler iD, Liza C Villaruz iD, John C Rhee, Bethany Horton iD, Joseph Mock, Michael Hanley iD, Kyeongmin Kim, Michelle A Rudek iD, Mitch A Phelps iD, Michael A Carducci iD, Richard Piekarz iD, Kwon-Sik Park iD und 2 weitere

The Oncologist · 2023

DOI: 10.1093/oncolo/oyad221 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, 2023. Verfasst von Ryan D Gentzler und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Neutropenia, Thrombocytopenia. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

CREBBP and EP300 mutations occur at a frequency of 15% and 13%, respectively, in small cell lung cancer (SCLC), and preclinical models demonstrated susceptibility to targeting with HDAC inhibitors.

Methods

Patients with treatment-naïve extensive-stage SCLC, ECOG ≤2 were enrolled and treated with entinostat orally weekly (4 dose levels, DL) in combination with standard dose carboplatin, etoposide, and atezolizumab. Cohort allocation was determined by Bayesian optimal interval (BOIN) design targeting an MTD with a DLT rate of 20%.

Results

Three patients were enrolled and treated at DL1 with entinostat 2 mg. Patients were aged 69-83; 2 male, 1 female; 2 were ECOG 1, and 1 was ECOG 0. The most common adverse events (AEs) were anemia (3), neutropenia (3), thrombocytopenia (2), leukopenia (2), and hypocalcemia (2). Two experienced DLTs during cycle 1: (1) grade (Gr) 4 febrile neutropenia, and (1) Gr 5 sepsis. BOIN design required stopping accrual to DL1, and the trial was closed to further accrual. Entinostat and atezolizumab pharmacokinetics were both comparable to historical controls.

Conclusion

Addition of entinostat to atezolizumab, carboplatin, and etoposide is unsafe and resulted in early onset and severe neutropenia, thrombocytopenia. Further exploration of entinostat with carboplatin, etoposide, and atezolizumab should not be explored. (ClinicalTrials.gov Identifier: NCT04631029).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsNeutropeniaThrombocytopeniaAnemiaHumansMaleFemaleEtoposideCarboplatinBayes TheoremAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedBenzamidesPyridines

Stichwörter der Autor:innen

atezolizumabcarboplatinentinostatetoposideimmunotherapysmall cell lung cancer

Substanzen

EtoposideCarboplatinatezolizumabAntibodies, Monoclonal, HumanizedentinostatBenzamidesPyridines

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh, PA, USA.
  • Department of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, VA, USA.
  • Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA.
  • Division of Pharmaceutics & Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA.
  • Department of Oncology and Medicine, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

ORCID-Profile: Ryan D Gentzler, Liza C Villaruz, Bethany Horton, Michael Hanley, Michelle A Rudek, Mitch A Phelps, Michael A Carducci, Richard Piekarz, Kwon-Sik Park, Timothy N Bullock, Charles M Rudin

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Gentzler, R. D., Villaruz, L. C., Rhee, J. C., Horton, B., Mock, J., Hanley, M., Kim, K., Rudek, M. A., Phelps, M. A., Carducci, M. A., Piekarz, R., Park, K. S., Bullock, T. N., & Rudin, C. M. (2023). Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. The Oncologist. https://doi.org/10.1093/oncolo/oyad221

Vancouver

Gentzler RD, Villaruz LC, Rhee JC, Horton B, Mock J, Hanley M, et al. Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399. The Oncologist. 2023. doi:10.1093/oncolo/oyad221

BibTeX
@article{Gentzler2023,
  author = {Gentzler, Ryan D and Villaruz, Liza C and Rhee, John C and Horton, Bethany and Mock, Joseph and Hanley, Michael and Kim, Kyeongmin and Rudek, Michelle A and Phelps, Mitch A and Carducci, Michael A and Piekarz, Richard and Park, Kwon-Sik and Bullock, Timothy N and Rudin, Charles M},
  title = {Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399},
  journal = {The Oncologist},
  year = {2023},
  doi = {10.1093/oncolo/oyad221}
}
Kostenlos starten →